Key result
Guideline-directed prasugrel is associated with similar clinically relevant bleeding rates as clopidogrel in ACS.
Why the study?
Does prasugrel compared to clopidogrel increase clinically relevant bleeding events in patients with acute coronary syndromes managed invasively?
Population
2,148 patients invasively managed for acute coronary syndromes enrolled in the multicentre Swiss ACS…
Comparison
Prasugrel vs Clopidogrel
Design
Cohort
Follow-up
1 year
Authors
Loading...
Supports comparable bleeding safety for guideline-directed prasugrel in ACS; leaves open causal inference without randomized evidence.
Cohort (n=2,148)
Yes
Does prasugrel compared to clopidogrel increase clinically relevant bleeding events in patients with acute coronary syndromes managed invasively?
Absolute Event Rate: 3.8% vs 5.5%
In a real-world ACS cohort, prasugrel used according to guidelines showed a similar safety profile to clopidogrel regarding clinically relevant bleeding at 1 year.
Klingenberg et al. (2015) conducted a cohort in Acute coronary syndromes (ACS) (n=2,148). Prasugrel vs. Clopidogrel was evaluated on Clinically relevant bleeding events (composite of BARC type 3, 4 or 5 bleeding). Prasugrel use according to guidelines in patients with acute coronary syndromes was associated with a similar rate of clinically relevant bleeding at 1 year compared to clopidogrel (3.8% vs 5.5%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: